Result: Risk Minimisation Materials for medicines starting with the letter D

Daptomycin

Accord Healthcare Limited

Daptomycin (Accord): Important safety information to minimise the risk of myotoxicity and dysregulation of in vivo coagulation-Dosage Card for Physicians

As part of the terms of the Marketing Authorisation for Daptomycin, Accord Healthcare Limited are required to ensure that all Healthcare Professionals who are likely to treat patients with daptomycin are provided with risk minimisation materials. This document contains key information to help minimize the risks of myotoxicity and dysregulation of in vivo coagulation. It also provides dosage recommendations and calculates the volume of volume of daptomycin 50 mg/ml solution that is required from the weight of the patient. If you require further information about daptomycin and hard copies of the material please contact medinfo@accord-healthcare.com. If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Daptomycin (Accord): Important safety information to minimise the risk of reduced susceptibility of S. aureus to daptomycin- The Laboratory Susceptibility Testing Leaflet

As part of the terms of the Marketing Authorisation for Daptomycin, Accord Healthcare Limited are required to ensure that all Healthcare Professionals who are likely to treat patients with daptomycin are provided with risk minimisation materials. This document contains key information to help minimise the risk of reduced susceptibility of S. aureus to daptomycin. It also provides a detailed explanation of the susceptibility testing issues, including the need for calcium in the testing medium. If you require further information about daptomycin and hard copies of the material please contact medinfo@accord-healthcare.com. If you have any questions or require additional information, please call Accord Healthcare Limited Medical Information Services on (0)1271 385 257.

For Healthcare Professionals

Darzalex

Janssen-Cilag Ltd

HCPs-_Important information on safety and risk minimisation of Daratumumab and interference with Blood Compatability Testing

Inform health care professionals of the interference of Darzalex (daratumumab) with antibody screening and crossmatching

For Healthcare Professionals

Important Information about Blood Transfusions

Card for patient's receiving Darzalex (daratumumab)- patient should carry this card while receiving treatment and for 6 months after treatment has ended.

Important information on safety and risk minimisation of Daratumumab and Interference with Blood Compatibility Testing

Information for Blood Banks on the intereference with Antiglobulin Test _blood typing

For Healthcare Professionals

DAXAS

AstraZeneca UK Limited

Daxas (roflumilast) Information for Patients

New COPD treatment patient card

Daxas (roflumilast) Information for Prescribers

For Healthcare Professionals

For Healthcare Professionals

Deltyba

Otsuka Novel Products GmbH

Deltyba - Information for patients on use during pregnancy or breastfeeding

An information card is available to aid counselling of women of child-bearing potential before initiating treatment with Deltyba.

For Healthcare Professionals

Deltyba - Risk minimisation information for healthcare providers

Important risk minimisation information for healthcare providers is available and should be read carefully before prescribing, dispensing or administering delamanid. Please ensure that each risk has been carefully considered and the relevant risk minimisation actions taken before initiating treatment.

For Healthcare Professionals

Depakote

SANOFI

Valproate Annual Risk Acknowledgement Form

For Hard copies of this information booklet please contact Sanofi medical information department on 0845 372 7101 or email UK-Medicalinformation@sanofi.com

Valproate- Healthcare professionals (HCPs) Educational material Pregnancy prevention programme

For Hard copies of this information booklet please contact Sanofi medical information department on 0845 372 7101 or email UK-Medicalinformation@sanofi.com

For Healthcare Professionals

Valproate- Letter for HCP- PREGNANCY PREVENTION PROGRAMME

For Hard copies of this information booklet please contact Sanofi medical information department on 0845 372 7101 or email UK-Medicalinformation@sanofi.com

For Healthcare Professionals

Valproate- Letter for Pharmacists- Pregnancy Prevention Programme

For Hard copies of this information booklet please contact Sanofi medical information department on 0845 372 7101 or email UK-Medicalinformation@sanofi.com

For Healthcare Professionals

Valproate- Patient Card-Contraception and Pregnancy Prevention

For Hard copies of this information booklet please contact Sanofi medical information department on 0845 372 7101 or email UK-Medicalinformation@sanofi.com

Valproate- Patient Guide-Educational material- Pregnancy prevention programme

For Hard copies of this information booklet please contact Sanofi medical information department on 0845 372 7101 or email UK-Medicalinformation@sanofi.com

Valproate- Poster- Dispensary- Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com .

For Healthcare Professionals

Valproate- White Box Warning Labels

For Hard copies of this information booklet please contact Sanofi medical information department on 0845 372 7101 or email UK-Medicalinformation@sanofi.com

Dexamethasone

Aspen

Dianette

Bayer plc

Dianette Patient Card UK

Dianette patient information card.

Dianette Prescriber Checklist UK

Dianette - checklist for prescribers.

For Healthcare Professionals

Disodium pamidronate

Wockhardt UK Ltd

Disodium Pamidronate Patient Reminder Card

Advice on the possible side effect osteonecrosis of the jaw (bone damage in the jaw).

Hospira UK Ltd

Pamidronate Patient Reminder Card

contains important safety information that patients need to be aware of before and during treatment with pamidronate disodium injections

Pamidronate Patient Reminder Card Cover Letter

is a letter which should be viewable only by the HCP. It details the requirement for the dispensing pharmacist to discuss the contents of the Patient Reminder Card with the patient prior to dispensing.

For Healthcare Professionals

medac GmbH

Pamidronate Patient Reminder Cards

This reminder card contains important safety information that you need to be aware of before and during treatment with Pamidronate 3 mg/ml infusions for cancer-related conditions

Domperidone

Wockhardt UK Ltd

Domperidone (Cardiac Effects) Adverse Drug Reaction Follow Up Form For Healthcare Professionals

Healthcare professionals As a result of the aforementioned procedure, Marketing Authorisation Holders (MAHs) in the EU for domperidone products have made a commitment to enhanced surveillance, by rigorous follow up of all reports of suspected adverse drug reactions (ADRs) involving domperidone. If you wish to report a suspected ADR concerning any type of cardiac effect, or any other kind of adverse effect, with Wockhardt UK Limited’s Domperidone 10mg Film-Coated Tablets or Domperidone 1mg/ml Oral Suspension, please complete the questionnaire entitled: ‘Domperidone (Cardiac Effects) Adverse Drug Reaction Follow Up Form For Healthcare Professionals' and return to the Drug Safety and Information Department by email (drug.safety@wockhardt.co.uk) or fax (+44 1978 669 430).

For Healthcare Professionals

Domperidone (Heart Associated Effects) Follow Up Form For Non-Healthcare Professionals

Patients As a result of the aforementioned procedure, Marketing Authorisation Holders (MAHs) in the EU for domperidone products have made a commitment to enhanced surveillance, by rigorous follow up of all reports of suspected adverse drug reactions (ADRs) involving domperidone. Patients must consult their doctor straight away if they suspect they have experienced an ADR whilst taking domperidone. If you wish to report a suspected ADR concerning any type of cardiac effect, or any other kind of adverse effect, with Wockhardt UK Limited’s Domperidone 10mg Film-Coated Tablets or Domperidone 1mg/ml Oral Suspension, please complete the questionnaire entitled: ‘Domperidone (Heart Associated Effects) Follow up Form For Non-Healthcare Professionals' and return to the Drug Safety and Information Department by email (drug.safety@wockhardt.co.uk) or fax (+44 1978 669 430).

Duodopa

AbbVie Ltd

Duodopa Best practice patient aftercare

This short guide provides advice to healthcare professionals on the management of patients with advanced Parkinson’s disease who have started Duodopa therapy

For Healthcare Professionals

Duodopa Critical Aspects of PEG-J Preparation Placement and Aftercare

The information presented in these slides is provided as part of additional Risk Minimisation Program for Duodopa targeted to minimise: –Gastrointestinal (GI) events –Device-related risks –Procedure-related risks associated with the levodopa – carbidopa intestinal gel (LCIG) system

For Healthcare Professionals

Duodopa PEG-J aftercare guideline

This guide provides advice to healthcare professionals on how to minimise PEG-J tube related complications in patients receiving Duodopa therapy. It should be used in conjunction with any local guidance and the CADD-Legacy 1400 pump instruction manual.

For Healthcare Professionals